Literature DB >> 22684144

Downregulation of TLR7/9 leads to deficient production of IFN-α from plasmacytoid dendritic cells in chronic hepatitis B.

Ning Xu1, Hang-Ping Yao, Guo-Cai Lv, Zhi Chen.   

Abstract

OBJECTIVE: To investigate whether Toll-like receptor (TLR) 7 and TLR9-mediated interferon α (IFN-α) production in plasmacytoid dendritic cells (pDCs) is compromised in patients with chronic hepatitis B virus (HBV) infection.
MATERIALS AND METHODS: Peripheral blood mononuclear cells (PBMCs) were prepared from 32 chronic HBV patients and 13 healthy volunteers, and treated with loxoribine or cytidine phosphate guanosine (CpG) oligodeoxynucleotides (ODN). Interferon α in the supernatant was measured by sandwich ELISA. PDC frequency and the expression levels of TLR7 and TLR9 in pDCs were quantified by flow cytometry. The serum viral load of HBV was quantified using a highly sensitive real-time PCR kit.
RESULTS: Compared to cells from healthy control group, PBMCs and pDCs from the HBV group showed significantly decreased production of IFN-α in response to ligand for TLR7 (loxoribine) and TLR9 (CpG ODN, P < 0.05). Mechanistically, the number of pDCs in peripheral blood, and the expression of pDC-associated TLR7 and TLR9 were significantly lower in HBV group than in the healthy control group (P < 0.05). In addition, the number of pDCs and the expression of TLR9 on pDCs were correlated inversely with the serum load of HBV.
CONCLUSION: Impaired IFN-α production from pDC may contribute to the immunopathogenesis of chronic HBV infection, which may be the result of a reduced amount of pDCs as well as decreased expression of TLR7 and TLR9 on pDCs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684144     DOI: 10.1007/s00011-012-0493-z

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  26 in total

Review 1.  Innate immune recognition: mechanisms and pathways.

Authors:  R Medzhitov; C Janeway
Journal:  Immunol Rev       Date:  2000-02       Impact factor: 12.988

Review 2.  Innate immune recognition.

Authors:  Charles A Janeway; Ruslan Medzhitov
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

3.  Toll-like receptors control activation of adaptive immune responses.

Authors:  M Schnare; G M Barton; A C Holt; K Takeda; S Akira; R Medzhitov
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

4.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

5.  Interferon-alpha generation and immune reconstitution during antiretroviral therapy for human immunodeficiency virus infection.

Authors:  F P Siegal; P Fitzgerald-Bocarsly; B K Holland; M Shodell
Journal:  AIDS       Date:  2001-09-07       Impact factor: 4.177

6.  Impaired functional capacities of liver dendritic cells from murine hepatitis B virus (HBV) carriers: relevance to low HBV-specific immune responses.

Authors:  A Hasebe; S M F Akbar; S Furukawa; N Horiike; M Onji
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

7.  Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9.

Authors:  Qing Xie; Huai-Cheng Shen; Ni-Na Jia; Hui Wang; Lan-Yi Lin; Bao-Yan An; Hong-Lian Gui; Si-Min Guo; Wei Cai; Hong Yu; Qing Guo; Shisan Bao
Journal:  Microbes Infect       Date:  2009-03-14       Impact factor: 2.700

8.  Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B.

Authors:  Renate G van der Molen; Dave Sprengers; Rekha S Binda; Esther C de Jong; Hubert G M Niesters; Johannes G Kusters; Jaap Kwekkeboom; Harry L A Janssen
Journal:  Hepatology       Date:  2004-09       Impact factor: 17.425

Review 9.  Dendritic cells: controllers of the immune system and a new promise for immunotherapy.

Authors:  Jacques Banchereau; Joseph Fay; Virginia Pascual; A Karolina Palucka
Journal:  Novartis Found Symp       Date:  2003

10.  Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors.

Authors:  M G Brook; P Karayiannis; H C Thomas
Journal:  Hepatology       Date:  1989-11       Impact factor: 17.425

View more
  18 in total

Review 1.  Immunopathogenesis of chronic hepatitis B.

Authors:  Irina P Balmasova; Nikolay D Yushchuk; Ospan A Mynbaev; Nageswara R Alla; Elena S Malova; Zhongjie Shi; Chang-Lu Gao
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 2.  Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses.

Authors:  Zhiyong Ma; Ejuan Zhang; Dongliang Yang; Mengji Lu
Journal:  Cell Mol Immunol       Date:  2014-11-24       Impact factor: 11.530

3.  Basis of HBV persistence and new treatment options.

Authors:  Mark Thursz
Journal:  Hepatol Int       Date:  2013-12-27       Impact factor: 6.047

Review 4.  Mesenchymal stem cells-based therapy in liver diseases.

Authors:  Heng-Tong Han; Wei-Lin Jin; Xun Li
Journal:  Mol Biomed       Date:  2022-07-27

5.  Functionally aberrant dendritic cell subsets and expression of DC-SIGN differentiate acute from chronic HBV infection.

Authors:  Sukriti Sukriti; Nirupma Trehanpati; Manoj Kumar; Chandana Pande; Syed S Hissar; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2016-09-22       Impact factor: 6.047

Review 6.  Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways.

Authors:  Rong-Juan Pei; Xin-Wen Chen; Meng-Ji Lu
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

7.  Microbial TLR Agonists and Humoral Immunopathogenesis in HIV Disease.

Authors:  Xiaocong Yu; Zihai Li; Zhenxian Zhou; J Michael Kilby; Wei Jiang
Journal:  Epidemiology (Sunnyvale)       Date:  2013-02-02

8.  Efficacy of a Virus-Like Nanoparticle As Treatment for a Chronic Viral Infection Is Hindered by IRAK1 Regulation and Antibody Interference.

Authors:  Karine Chartrand; Marie-Ève Lebel; Esther Tarrab; Pierre Savard; Denis Leclerc; Alain Lamarre
Journal:  Front Immunol       Date:  2018-01-04       Impact factor: 7.561

Review 9.  Molecular Mechanisms during Hepatitis B Infection and the Effects of the Virus Variability.

Authors:  Marina Campos-Valdez; Hugo C Monroy-Ramírez; Juan Armendáriz-Borunda; Laura V Sánchez-Orozco
Journal:  Viruses       Date:  2021-06-18       Impact factor: 5.048

Review 10.  Toll-like receptor 9 in breast cancer.

Authors:  Jouko Sandholm; Katri S Selander
Journal:  Front Immunol       Date:  2014-07-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.